About Our Facilities
Advanced Cell Therapy and Research Institute, Singapore (“ACTRIS”) at National Cancer Center, Singapore (“NCCS”) Building will comprise of a current Good Manufacturing Practice (“cGMP”) Facility and a Good Tissue Practice (“GTP”) Facility that will serve to meet the increasing demand for cell, tissue and gene therapy (CTGT) products process development and manufacturing as well as related translational research in Singapore and the surrounding ASEAN region.
The facility is envisioned to house state-of-art technologies that will enable manufacturing of CTGT products to serve both the public and private sector of Singapore. The upcoming facility aims to attain all national level certifications/accreditations that will be administered by Health Science Authority and Ministry of Health, Singapore with regards to CTGT manufacturing. ACTRIS will also aim to meet CTGT manufacturing standards set by international organisations and regulatory authorities such as FDA, PIC/S, EMA and ISCT. The facility will work towards attaining international accreditation such as FACT/JACIE and is anticipated to be fully operational by 1st Quarter of 2022, with National Certification for CTGT in keeping with cGMP standards of practice being completed by early-2023.
The current operations of ACTRIS will be carried out in 2 existing facilities in Health Sciences Authority, HSA and National University Health System, NUHS.
The Cell Therapy Facility, CTF, in HSA has 4 Grade B suites and a QC laboratory. They fulfil cGMP and GTP requirements by PIC/S and HSA and is also JACIE accredited and FACT compliance. (Refer to link for CTF webpage)
The Tissue Engineering and Cellular Therapy Lab, TECT, in NUHS comprises of certified cleanrooms with capabilities that include flow cytometry and cell selection. The facility is FACT-JACIE accredited and met the requirements by PIC/S and HSA. (Refer to link for TECT lab webpage).
Pictures shown are placeholders, and are not representative of the actual facilities that will be completed in 2022.